Regeneron Announces Investor Conference Presentations
- Cowen 42nd Annual
Health Care Conferenceat 1:30 p.m. ETon Tuesday, March 8, 2022
- Oppenheimer 32nd Annual Healthcare Conference at
10:00 a.m. ETon Tuesday, March 15, 2022 Barclays Global Healthcare Conferenceat 8:00 a.m. ETon Wednesday, March 16, 2022
The sessions may be accessed from the "Investors & Media" page of Regeneron's website at https://investor.regeneron.com/events-and-presentations. Replays of the webcasts will be archived on the Company's website for at least 30 days.
Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune®, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.
For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.